JP2021522303A5 - - Google Patents

Info

Publication number
JP2021522303A5
JP2021522303A5 JP2020561788A JP2020561788A JP2021522303A5 JP 2021522303 A5 JP2021522303 A5 JP 2021522303A5 JP 2020561788 A JP2020561788 A JP 2020561788A JP 2020561788 A JP2020561788 A JP 2020561788A JP 2021522303 A5 JP2021522303 A5 JP 2021522303A5
Authority
JP
Japan
Prior art keywords
region
substitution
sequence shown
seq
antibody
Prior art date
Application number
JP2020561788A
Other languages
English (en)
Japanese (ja)
Other versions
JP7649139B2 (ja
JP2021522303A (ja
JPWO2019211472A5 (https=
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2019/061455 external-priority patent/WO2019211472A1/en
Publication of JP2021522303A publication Critical patent/JP2021522303A/ja
Publication of JP2021522303A5 publication Critical patent/JP2021522303A5/ja
Publication of JPWO2019211472A5 publication Critical patent/JPWO2019211472A5/ja
Priority to JP2025035978A priority Critical patent/JP2025085008A/ja
Application granted granted Critical
Publication of JP7649139B2 publication Critical patent/JP7649139B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020561788A 2018-05-03 2019-05-03 抗体バリアントの組み合わせおよびその使用 Active JP7649139B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025035978A JP2025085008A (ja) 2018-05-03 2025-03-07 抗体バリアントの組み合わせおよびその使用

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DKPA201800195 2018-05-03
DKPA201800195 2018-05-03
DKPA201800644 2018-09-26
DKPA201800644 2018-09-26
PCT/EP2019/061455 WO2019211472A1 (en) 2018-05-03 2019-05-03 Antibody variant combinations and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025035978A Division JP2025085008A (ja) 2018-05-03 2025-03-07 抗体バリアントの組み合わせおよびその使用

Publications (4)

Publication Number Publication Date
JP2021522303A JP2021522303A (ja) 2021-08-30
JP2021522303A5 true JP2021522303A5 (https=) 2022-05-13
JPWO2019211472A5 JPWO2019211472A5 (https=) 2022-05-13
JP7649139B2 JP7649139B2 (ja) 2025-03-19

Family

ID=66476613

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020561788A Active JP7649139B2 (ja) 2018-05-03 2019-05-03 抗体バリアントの組み合わせおよびその使用
JP2025035978A Pending JP2025085008A (ja) 2018-05-03 2025-03-07 抗体バリアントの組み合わせおよびその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025035978A Pending JP2025085008A (ja) 2018-05-03 2025-03-07 抗体バリアントの組み合わせおよびその使用

Country Status (13)

Country Link
US (1) US12338289B2 (https=)
EP (1) EP3788074A1 (https=)
JP (2) JP7649139B2 (https=)
KR (1) KR20210008380A (https=)
CN (1) CN112839958A (https=)
AU (1) AU2019264217B2 (https=)
BR (1) BR112020022179A2 (https=)
CA (1) CA3098486A1 (https=)
MA (1) MA52485A (https=)
MX (1) MX2020011552A (https=)
PH (1) PH12020551808A1 (https=)
SG (1) SG11202010601VA (https=)
WO (1) WO2019211472A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250140128A (ko) 2017-02-10 2025-09-24 젠맵 비. 브이 폴리펩티드 변이체 및 그의 용도
MX2022007202A (es) * 2019-12-13 2022-10-07 Cugene Inc Fármacos bioactivables a base de citocinas y metodos de uso de los mismos.
EP4136107A4 (en) * 2020-04-17 2024-05-08 Janssen Biotech, Inc. Biosynthetic glycoprotein populations
GB2595299B (en) 2020-05-21 2022-08-03 Mabsolve Ltd Modified immunoglobulin FC regions
US20240150484A1 (en) * 2021-03-12 2024-05-09 Genmab A/S Non-activating antibody variants
JP2024540951A (ja) * 2021-10-20 2024-11-06 ヤンセン バイオテツク,インコーポレーテツド 増強されたエフェクター機能を有する生体合成バイパラトピック又は二重特異性結合分子
EP4644413A1 (en) 2024-05-03 2025-11-05 Genmab B.V. Binding agents having altered fc-mediated effector functions
WO2025228542A1 (en) 2024-05-03 2025-11-06 Genmab B.V. Method for co-expression of a plurality of antibodies

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4213224B2 (ja) 1997-05-02 2009-01-21 ジェネンテック,インコーポレーテッド ヘテロマルチマー及び共通成分を有する多重特異性抗体の製造方法
ES2434961T5 (es) 1998-04-20 2018-01-18 Roche Glycart Ag Ingeniería de glicosilación de anticuerpos para mejorar la citotoxicidad celular dependiente del anticuerpo
EP1176195B1 (en) 1999-04-09 2013-05-22 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
CA2388245C (en) 1999-10-19 2012-01-10 Kyowa Kirin Co., Ltd. The use of serum-free adapted rat cells for producing heterologous polypeptides
US7521047B2 (en) 2000-05-12 2009-04-21 Gpc Biotech Ag Human polypeptides causing or leading to the killing of cells including lymphoid tumor cells
DE10043437A1 (de) 2000-09-04 2002-03-28 Horst Lindhofer Verwendung von trifunktionellen bispezifischen und trispezifischen Antikörpern zur Behandlung von malignem Aszites
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
ES2639222T5 (es) 2000-10-06 2023-11-24 Kyowa Kirin Co Ltd Células que producen unas composiciones de anticuerpo
CA2424977C (en) 2000-10-06 2008-03-18 Kyowa Hakko Kogyo Co., Ltd. Process for purifying antibody
HUP0600342A3 (en) 2001-10-25 2011-03-28 Genentech Inc Glycoprotein compositions
NZ537277A (en) 2002-07-18 2008-04-30 Crucell Holland Bv Recombinant production of mixtures of antibodies
CN101928344B (zh) 2002-10-17 2014-08-13 根马布股份公司 抗cd20的人单克隆抗体
US7741568B2 (en) 2005-01-13 2010-06-22 The Wiremold Company Downward facing receptacle assembly for cable raceway
ES2665422T3 (es) 2005-03-03 2018-04-25 Immunomedics Inc. Anticuerpos L243 humanizados
EP3050963B1 (en) 2005-03-31 2019-09-18 Chugai Seiyaku Kabushiki Kaisha Process for production of polypeptide by regulation of assembly
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
US10155816B2 (en) 2005-11-28 2018-12-18 Genmab A/S Recombinant monovalent antibodies and methods for production thereof
KR101516823B1 (ko) 2006-03-17 2015-05-07 바이오겐 아이덱 엠에이 인코포레이티드 안정화된 폴리펩티드 조성물
US8871912B2 (en) 2006-03-24 2014-10-28 Merck Patent Gmbh Engineered heterodimeric protein domains
CN101074261A (zh) 2006-04-30 2007-11-21 北京同为时代生物技术有限公司 Trail受体1和/或trail受体2特异性抗体及其应用
AT503902B1 (de) 2006-07-05 2008-06-15 F Star Biotech Forsch & Entw Verfahren zur manipulation von immunglobulinen
EP3424951A1 (en) 2007-06-21 2019-01-09 MacroGenics, Inc. Covalent diabodies and uses thereof
EP2050764A1 (en) 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
ES2563027T3 (es) 2008-01-07 2016-03-10 Amgen Inc. Método para fabricación de moléculas heterodímeras Fc de anticuerpos utilizando efectos de conducción electrostática
EP2376109B1 (en) 2008-12-19 2019-01-23 MacroGenics, Inc. Covalent diabodies and uses thereof
JP2012525149A (ja) 2009-04-27 2012-10-22 オンコメッド ファーマシューティカルズ インコーポレイテッド ヘテロ多量体分子を作製するための方法
EP2430051B1 (en) 2009-05-14 2016-03-23 Institut National de la Santé et de la Recherche Medicale Compositions containing antibodies for treating cd5+ hla-dr+ b or t cell related diseases
JP5816170B2 (ja) 2009-06-26 2015-11-18 リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. 天然の免疫グロブリン形式を有する容易に単離される二重特異性抗体
US9493578B2 (en) 2009-09-02 2016-11-15 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
EP2507381A4 (en) 2009-12-04 2016-07-20 Hoffmann La Roche MULTISPECIFIC ANTIBODIES, ANTIBODY ANALOGS, COMPOSITIONS AND METHODS
SG183542A1 (en) 2010-03-12 2012-10-30 Immunogen Inc Cd37-binding molecules and immunoconjugates thereof
TWI426920B (zh) 2010-03-26 2014-02-21 Hoffmann La Roche 雙專一性、雙價抗-vegf/抗-ang-2抗體
DK2560993T3 (da) 2010-04-20 2024-10-14 Genmab As Heterodimeric antibody fc-containing proteins and methods for production thereof
US9527926B2 (en) 2010-05-14 2016-12-27 Rinat Neuroscience Corp. Heterodimeric proteins and methods for producing and purifying them
JP6055404B2 (ja) 2010-06-15 2016-12-27 ゲンマブ エー/エス 組織因子に対するヒト抗体薬物結合体
PL2606064T3 (pl) 2010-08-16 2015-07-31 Novimmune Sa Sposoby wytwarzania wieloswoistych i wielowartościowych przeciwciał
WO2012025530A1 (en) 2010-08-24 2012-03-01 F. Hoffmann-La Roche Ag Bispecific antibodies comprising a disulfide stabilized - fv fragment
MX340556B (es) 2010-08-24 2016-07-14 Roche Glycart Ag Anticuerpos biespecificos activables.
PL2635607T3 (pl) 2010-11-05 2020-05-18 Zymeworks Inc. Projekt stabilnego przeciwciała heterodimerowego z mutacjami w domenie FC
SG10201602394QA (en) 2011-03-29 2016-05-30 Roche Glycart Ag Antibody FC Variants
GB201109238D0 (en) 2011-06-01 2011-07-13 Antitope Ltd Antibodies
CN102250246A (zh) 2011-06-10 2011-11-23 常州亚当生物技术有限公司 抗VEGF/PDGFRβ双特异性抗体及其应用
UA117901C2 (uk) 2011-07-06 2018-10-25 Ґенмаб Б.В. Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування
LT2794905T (lt) 2011-12-20 2020-07-10 Medimmune, Llc Modifikuoti polipeptidai, skirti bispecifinių antikūnų karkasams
SI2838917T1 (sl) 2012-04-20 2019-11-29 Merus Nv Postopki in sredstva za produkcijo heterodimernih IG-podobnih molekul
BR112015000167B1 (pt) 2012-07-06 2021-11-23 Genmab B.V. Proteína dimérica, proteína, composição, kit de partes e seus usos, bem como método para aumentar a oligomerização em solução de uma proteína dimérica compreendendo um primeiro e segundo polipeptídeo, cada um compreendendo pelo menos as regiões ch2 e ch3 de uma cadeia pesada de igg1 humana e proteína dimérica variante
ES2758979T3 (es) 2012-07-06 2020-05-07 Genmab Bv Proteína dimérica con mutaciones triples
EP2684896A1 (en) 2012-07-09 2014-01-15 International-Drug-Development-Biotech Anti-DR5 family antibodies, bispecific or multivalent anti-DR5 family antibodies and methods of use thereof
JP2015527366A (ja) 2012-08-20 2015-09-17 グリックニック インコーポレイテッド 抗原結合および多価fcガンマ受容体結合活性を有する分子
KR20200024345A (ko) 2013-01-10 2020-03-06 젠맵 비. 브이 인간 IgG1 Fc 영역 변이체 및 그의 용도
CN106255704A (zh) 2014-04-16 2016-12-21 Ucb生物制药私人有限公司 多聚体Fc蛋白
AU2016246695A1 (en) * 2015-04-07 2017-10-26 Genentech, Inc. Antigen binding complex having agonistic activity and methods of use
MA43365A (fr) 2015-12-01 2018-10-10 Genmab Bv Anticorps anti-dr5 et procédés d'utilisation de ceux-ci
US11459405B2 (en) * 2015-12-28 2022-10-04 Massachusetts Institute Of Technology Bispecific antibodies having constant region mutations and uses therefor
WO2018031258A1 (en) 2016-08-12 2018-02-15 Janssen Biotech, Inc. Engineered antibodies and other fc-domain containing molecules with enhanced agonism and effector functions
KR20250140128A (ko) 2017-02-10 2025-09-24 젠맵 비. 브이 폴리펩티드 변이체 및 그의 용도
US20230399414A1 (en) 2017-03-31 2023-12-14 Genmab Holding B.V, Bispecific anti-cd37 antibodies, monoclonal anti-cd37 antibodies and methods of use thereof
EP3601354A1 (en) 2017-03-31 2020-02-05 Genmab Holding B.V. Bispecific anti-cd37 antibodies, monoclonal anti-cd37 antibodies and methods of use thereof
CN111328335A (zh) 2017-06-07 2020-06-23 根马布私人有限公司 基于突变igg六聚体的治疗性抗体
TWI874341B (zh) 2018-12-18 2025-03-01 美商健生生物科技公司 產生異二聚體抗體之方法
US20220411529A1 (en) 2019-11-06 2022-12-29 Genmab B.V. Antibody variant combinations and uses thereof

Similar Documents

Publication Publication Date Title
JP2021522303A5 (https=)
CN110891650B (zh) 制导和导航控制蛋白及其制造和使用方法
US11202828B2 (en) Therapeutic SIRP-α antibodies
ES2460517T3 (es) Reducción de células b mediante el uso de moléculas de unión específica a cd37 y de unión específica a cd20
CN113454119B (zh) 抗btla抗体
CN111484555B (zh) 新型双特异性cd3/cd20多肽复合物
EP4249066A2 (en) Antibodies to tigit
CN109862910A (zh) 破坏巨噬细胞上的Fc受体接合增强抗SIRPα抗体疗法的功效
JP2019503363A (ja) 急性リンパ芽球性白血病を治療するための二重特異性の抗cd20/抗cd3抗体
CN114456272A (zh) 靶向afp肽/mhc复合体的构建体及其用途
JP2021510736A5 (https=)
JP2020516309A5 (https=)
KR20250024104A (ko) 다중-특이적 항체 및 이를 제조하는 방법 및 이의 용도
WO2022243838A1 (en) Compositions comprising a t cell redirection therapeutic and an anti-cd44 therapeutic
CN112292399A (zh) 抗cd27抗体及其用途
JP2021522303A (ja) 抗体バリアントの組み合わせおよびその使用
JP2024073580A (ja) Btla抗体
TWI889761B (zh) Cd137結合分子及其用途
JPWO2019211472A5 (https=)
JPWO2021068841A5 (https=)
CN113975385A (zh) 新型双特异性抗cd3/cd20多肽复合物配制剂
Gupta et al. Therapeutic human monoclonal antibodies
RU2827062C1 (ru) Антитело анти-pvrig протеин или фрагмент антитела и их использование
WO2023179443A1 (en) Anti-her2/anti-cd47 molecules and uses thereof
Ebadi et al. Immunopathology and Immunotherapy of Non-Hodgkin Lymphoma